Perception Neuroscience is a clinical-stage company whose glutamatergic drug R-ketamine (PCN-101) completed a Phase 1 study for treatment-resistant depression.
There's no better way to help than to get out and experience nature for yourself. Donec id elit non mi porta gravida at eget metus. Donec sed odio dui. Maecenas faucibus mollis interdum. Duis mollis, est non commodo luctus, nisi erat porttitor ligula, eget lacinia odio sem nec elit. Nullam id dolor
Perception Neurosciences, an atai Life Sciences subsidiary, Announces Additional Analyses from the Phase 2a Trial of PCN-101 (R-ketamine) at the ASCP 2023 Annual Meeting
Yet as Dr. Terence Kelly, CEO of Perception Neuroscience, noted, the regulatory authorities are very familiar with psychedelic substances and tend to be cooperative regarding their research.
Perception Neuroscience begins a Phase 1 study comparing subcutaneous and intravenous doses of PCN-101 (R-ketamine) to assess pharmacokinetics and tolerability.
Perception Neuroscience announces the appointments of Maju Mathews, MD, as Chief Medical Officer and Cedric Burg, PhD as Senior Vice President, Clinical Operations.
Cedric Burg graduated from American University in Washington D.C. with a Bachelor’s Degree in Biology and went on to obtain a Ph.D. in Pharmacology from the University of Nantes, France.
Mouhannad Jumaa worked with Perception since 2018 and joined the company full-time in 2021 with over 20 years of experience in the pharmaceutical industry.
Otsuka Pharmaceutical partners with Perception Neuroscience (an atai Life Sciences company) to develop and commercialize **PCN-101 (R-ketamine)** in Japan for treating **major depressive disorder (MDD) and treatment-resistant depression (TRD)**. Perception holds global development rights outside Japan for the same indication. The collaboration focuses on advancing the molecule’s clinical and commercial potential in the Japanese market.
Atai Life Sciences cuts 30% of its workforce following the failure of its ketamine-like drug in a phase 2 depression trial. The company redirects resources to advance its remaining mid-stage trial candidates in mental health. The layoffs occur just two months after the setback in clinical development.
atai Life Sciences reports that its PCN-101 (R-ketamine) candidate did not meet the primary endpoint in a Phase 2a trial for treatment-resistant depression (TRD). The proof-of-concept study, completed on November 10, 2022, marks a setback in the company’s efforts to develop a novel therapy for TRD. The trial results highlight challenges in advancing the drug as an accessible alternative for patients.
Researchers identify a neuron-to-neuron connection type that may clarify how ketamine influences depression treatment. The study highlights a potential biological mechanism underlying ketamine’s rapid antidepressant effects, offering insights into its therapeutic pathways. Findings focus on neural signaling patterns linked to mood regulation.
atai Life Sciences receives FDA investigational new drug (IND) clearance for PCN-101, a ketamine-based compound, ahead of its upcoming clinical study. The designation allows the company to proceed with human trials to evaluate the drug’s safety and efficacy. PCN-101 is being developed as a potential treatment for psychiatric conditions.
ATAI Life Sciences acquires a majority stake in Perception Neuroscience to advance **arketamine**-based therapies for neuropsychiatric disorders. The New York-based biopharmaceutical company, founded by Jonathan Sporn and Jay Kranzler—both with pharmaceutical R&D leadership experience—will retain minority ownership. Perception focuses on innovative neuropsychiatry treatments and has received advisory support from PJT Partners.